RTP Mobile Logo
Real-Life Decisions: Proceedings from a Case-Based Symposium on the Management of Early and Advanced Breast Cancer
Released April 2011

Featuring Faculty Perspectives on New Data Sets Presented at the 33rd Annual San Antonio Breast Cancer Symposium. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Breast cancer is one of the most rapidly evolving fields in medical oncology. Results from numerous ongoing trials lead to the continual emergence of new therapeutic agents, treatment strategies and diagnostic and prognostic tools. To bridge the gap between research and patient care, these proceedings from a case-based CME satellite symposium at the 2010 San Antonio Breast Cancer Symposium use the perspectives of clinical investigators, in addition to the exchange among these individuals, to apply evidence-based concepts to routine practice. By providing access to the latest research developments and expert opinions on the disease, this activity will assist medical oncologists and hematology-oncology fellows in the formulation of up-to-date clinical management strategies for breast cancer.

    LEARNING OBJECTIVES

    • Use currently available tissue-based genomic assays to assist with therapeutic decision-making in the management of node-negative and node-positive early breast cancer.
    • Apply the results of recent clinical research when recommending HER2-directed therapy for patients with trastuzumab-naïve and previously exposed breast cancer.
    • Communicate the benefit-risk profile of bevacizumab and its evidence-based therapeutic partners to appropriate patients with metastatic breast cancer.
    • Counsel appropriately selected patients with breast cancer about the supportive and therapeutic roles of bisphosphonates in disease management.
    • Employ case-based learning to the individualized selection of endocrine therapy for patients with newly diagnosed or progressive estrogen receptor-positive breast cancer.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    CME credit is no longer available for this issue

    This CME activity contains an audio component. The participant should listen to the audio MP3s.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY
    — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Howard A Burris III, MD

    Chief Medical Officer
    Director, Drug Development
    Sarah Cannon Research Institute
    Nashville, Tennessee

    No real or apparent conflicts of interest to disclose.

    Eric P Winer, MD

    Thompson Investigator in Breast Cancer Research
    Chief, Division of Women’s Cancers
    Dana-Farber Cancer Institute
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    No real or apparent conflicts of interest to disclose.

    Clifford Hudis, MD
    Chief, Breast Cancer Medicine Service
    Solid Tumor Division
    Department of Medicine
    Memorial Sloan-Kettering Cancer Center
    Professor of Medicine
    Weill Cornell Medical College
    New York, New York

    Paid Research:
    Merck and Company Inc, Onyx Pharmaceuticals Inc.

    Mark D Pegram, MD
    Professor of Medicine
    Acting Chief, Division of Hematology/Oncology
    Associate Director for Clinical Research
    UM Sylvester Comprehensive Cancer Center
    Director for Clinical and Translational Research Program
    Braman Family Breast Cancer Institute
    Miami, Florida

    Advisory Committee:
    Amgen Inc, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Sanofi-Aventis; Consulting Agreements: Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi-Aventis; Data and Safety Monitoring Board: Wyeth; Paid Research: Genentech BioOncology, Sanofi-Aventis; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Pfizer Inc, Sanofi-Aventis.

    Joseph A Sparano, MD

    Professor of Medicine and Women's Health
    Albert Einstein College of Medicine
    Associate Chairman, Department of Oncology
    Montefiore Medical Center
    Bronx, New York

    Advisory Committee:
    Abraxis BioScience, Bristol-Myers Squibb Company, Eisai Inc, Genentech BioOncology, Pfizer Inc; Consulting Agreements: Eisai Inc; Speakers Bureau: Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline.

    MODERATOR
    Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium — The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS
    — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Genomic Health Inc.


    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: April 2011
    Expiration date: April 2012

Acknowledge and close

Listen to audio: